DXC012

DXC012 is an investigational antibody-drug conjugate (ADC) being developed by Hangzhou DAC Biotech for the treatment of solid tumors. Currently in the preclinical stage of development, DXC012 is part of a specialized pipeline that leverages proprietary conjugation technologies to link monoclonal antibodies with potent cytotoxic payloads. While the specific molecular target and the identity of the payload for DXC012 have not been publicly disclosed by the developer, the candidate is designed to selectively deliver anti-cancer agents to malignant cells expressing a specific surface antigen, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. Hangzhou DAC Biotech utilizes various proprietary linker-payload platforms, such as their D-S (disulfide) and D-A (amide) systems, to optimize the stability and release profiles of their ADC candidates.